Form 4: Cytek Biosciences' Chief Legal Officer Reports Stock Transactions

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the acquisition and disposal of common stock and restricted stock units related to vesting and tax obligations.

Summary

• On August 19, 2024, Valerie Barnett, the Chief Legal Officer of Cytek Biosciences, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
• Barnett acquired shares through the vesting of RSUs and disposed of shares to cover tax obligations related to these vestings.
• Specifically, Barnett acquired 2,016, 3,681, and 7,735 shares through RSU vesting.
• Simultaneously, she disposed of 786, 1,434, and 2,826 shares to satisfy tax withholding requirements at a price of $5.53 per share.
• Following these transactions, Barnett directly owns 53,917 shares of Cytek Biosciences common stock and holds 110,871 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports routine stock transactions related to executive compensation. There are no explicit positive or negative implications for the company's performance.

Positives

• The vesting of RSUs indicates that performance milestones or time-based vesting requirements have been met.

Negatives

• The disposal of shares to cover tax obligations, while routine, slightly reduces Barnett's holdings in the company.

Risks

• There are no specific risks highlighted in this document; it primarily details stock transactions related to compensation.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• Companies like Danaher, Agilent, and Thermo Fisher Scientific also have executives who regularly file Form 4s related to stock options and RSU vesting.
• The vesting schedules and tax withholding practices described are typical for executive compensation packages in the biotech industry.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive stock ownership.
• Employees holding RSUs are impacted by the vesting schedules and associated tax obligations.

Key Dates